Lv4
626 积分 2025-08-28 加入
Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients
17小时前
待确认
Pooled analysis by best confirmed response to trastuzumab deruxtecan and related biomarkers in patients with HER2-positive metastatic breast cancer from DESTINY-Breast01, DESTINY-Breast02, and DESTINY-Breast03
17小时前
已完结
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer-The ETOP NICOLAS trial
27天前
已完结
[Guidelines for the prevention and management of bronchial asthma (2024 edition)]
1个月前
已完结
Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study
1个月前
已完结
Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Brain Metastases Working Group
1个月前
已关闭
First-line PD-1/VEGF bispecific antibody plus chemotherapy in triple-negative breast cancer: a phase 2 trial
1个月前
已完结
The next generation of antibody–drug conjugates
2个月前
已完结
Clinical toxicity of ADCs and ICI-ADC combinations: mechanisms, patterns and management
2个月前
已完结
Response assessment criteria for brain metastases: proposal from the RANO group
2个月前
已完结
皖公网安备34019202002308
